ST Renfu (600079.SH): Carbamazepine extended-release tablets (II) obtained drug registration certificate

Zhitongcaijing · 2d ago

Zhitong Finance App News, ST Renfu (600079.SH) announced that the company's holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (“Yichang Renfu”, the company holds 80% of its shares) recently received the “Drug Registration Certificate” for carbamazepine sustained-release tablets (II) approved and issued by the State Drug Administration. Carbamazepine sustained-release tablets (II) are mainly used to treat seizures, including partial seizures, primary or secondary generalized tonic-clonic seizures, and mixed seizures; to relieve trigeminal neuralgia, including trigeminal neuralgia due to multiple sclerosis, primary trigeminal neuralgia, and primary glossopharyngeal neuralgia.